Recurrent exacerbations affect FEV1 decline in adult patients with cystic fibrosis

Respiratory Medicine

Volumn 103, Issue 3, 2009, Pages 407-413

  Amadori, Anna ^a   Antonelli, Andrea ^a   Balteri, Ilaria ^a   Schreiber, Anja ^a   Bugiani, Massimiliano ^b   De Rose, Virginia ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Local Health Unit 4   (Italy)

Author keywords

Cystic fibrosis in adults; Exacerbations; FEV1 decline

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BODY HEIGHT; BODY WEIGHT; CLINICAL ASSESSMENT; CORRELATION ANALYSIS; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE EXACERBATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; GENOTYPE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PANCREAS FUNCTION; PANCREAS INSUFFICIENCY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DISEASE PROGRESSION; EXOCRINE PANCREATIC INSUFFICIENCY; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 59549085848     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2008.09.024     Document Type: Article

References (38)

1. Davis P.B., Drumm K., and Konstan M.W. Cystic fibrosis: state of the art. Am J Respir Crit Care Med 154 (1996) 1229-1256
2. Ratjen F., and Doring G. Cystic fibrosis. Lancet 361 (2003) 681-689
3. Zielenski J., and Tsui L.C. Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet 29 (1995) 777-807
4. Kerem E., and Kerem B. Genotype-phenotype correlation in cystic fibrosis. Pediatr Pulmonol 22 (1996) 387-395
5. Corey M., Edwards L., Levison H., and Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 131 (1997) 809-814
6. Schluchter M.D., Konstan M.W., and Davis P.B. Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients. Stat Med 21 (2002) 1271-1287
7. Nelson L.A., Callerame M.L., and Schwartz R.H. Aspergillosis and atopy in cystic fibrosis. Am Rev Respir Dis 120 (1979) 863-873
8. Stevens D.A., Moss R.B., Kurup V.P., et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis - state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 37 Suppl. 3 (2003) S225-S264
9. Beharry S., Ellis L., Corey M., Marcon M., and Durie P. How useful is fecal pancreatic elastase 1 as a marker of exocrine pancreatic disease?. J Pediatr 141 (2002) 84-90
10. Moran A., Hardin D., Rodman D., et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract 54 (1999) 61-73
11. Doring G., Conway S.P., Heijerman, et al. Consensus statement: antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 16 (2000) 749-767
12. De Rose V., Oliva A., Messore B., Grosso B., Mollar C., and Pozzi E. Circulating adhesion molecules in cystic fibrosis. Am J Respir Crit Care Med 157 (1998) 1234-1239
13. Cystic Fibrosis Foundation. Clinical practice guidelines for cystic fibrosis (1997), Cystic Fibrosis Foundation, Bethesda, MD
14. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 152 (1995) 1107-1136
15. De Rose V., Arduino C., Cappello N., et al. Fcgamma receptor IIA genotype and susceptibility to P. aeruginosa infection in patients with cystic fibrosis. Eur J Hum Genet 13 (2004) 96-101
16. Rabe-Hesketh S., and Skrondal A. Multilevel and longitudinal modeling using Stata-Cho 3-3 linear random-coefficient and growth-curve models (2005), Stata Press, College Station, Texas, USA
17. Twisk J.W.R. Applied longitudinal data analysis for epidemiology (2003), Cambridge University Press, Cambridge, UK
18. Demko C.A., Byard P.J., and Davis P.B. Gender difference in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol 48 (1995) 712-718
19. Davis P.B., Byard P.J., and Konstan M.W. Identifying treatments that halt progression of pulmonary disease in cystic fibrosis. Pediatr Res 41 (1997) 161-165
20. Zemel B.S., Jaward A.F., FitzSimmons S., and Stallings V.A. Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patients Registry. J Pediatr 137 (2000) 374-380
21. Steinkamp G., and Wiedemann B. Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax 57 (2002) 596-601
22. Schaedel C., de Monestrol I., Hjelte L., et al. Predictor of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol 33 (2002) 483-491
23. Lewin L.O., Byard P.J., and Davis P.B. Effects of Pseudomonas cepacia colonization on survival and pulmonary function of cystic fibrosis patients. J Clin Epidemiol 43 (1990) 125-131
24. Kerem E., Corey M., Gold M., and Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr 116 (1990) 1653-1658
25. Downey D.G., Martin S.L., Dempster M., et al. The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis. Pediatr Pulmonol 42 (2007) 216-220
26. Konstan M.J., Morgan W.J., Butler S.M., et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 151 (2007) 134-139
27. Martinez-Garcia M.A., Soler-Cataluna J.J., Perpina-Tordera M., Roman-Sanchez P., and Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 132 (2007) 1565-1572
28. Ellaffi M., Vinsonneau C., Coste J., et al. One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis. Am J Respir Crit Care Med 171 (2005) 158-164
29. Ferkol T., Rosenfeld M., and Milla C.E. Cystic fibrosis pulmonary exacerbations. J Pediatr 148 (2006) 259-264
30. De Rose V. Mechanisms and markers of airways inflammation in cystic fibrosis. Eur Respir J 19 (2002) 333-340
31. Downey D.G., Brockbank S., Martin L., Ennis M., and Elborn J.S. The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation. Pediatr Pulmonol 42 (2007) 729-735
32. Roberts H.R., Wells A.U., Milne D.G., et al. Airflow obstruction in bronchiectasis: correlation between computed tomography features and pulmonary function tests. Thorax 55 (2000) 198-204
33. de Jong P.A., Nakano Y., Lequin M.H., et al. Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis. Eur Respir J 23 (2004) 93-97
34. Martinez-Garcia M.A., Perpina-Tordera M., Soler-Cataluna J.J., Roman-Sanchez P., Lloris-Bayo A., and Gonzales-Molina A. Dissociation of lung function, dyspnea ratings and pulmonary extension in bronchiectasis. Respir Med 101 (2007) 2248-2253
35. Navarro J., Rainisio M., Harms H.K., et al. Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. Eur Respir J 18 (2001) 298-305
36. Lanng S., Thorsteinsson B., Nerup J., and Koch C. Diabetes mellitus in cystic fibrosis: effects of insulin therapy on lung function and infections. Acta Pediatr 83 (1994) 849-853
37. Lanng S., Thorsteinson B., Nerup J., and Koch C. Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr 151 (1992) 684-687
38. Koch C., Rainisio M., Madessani U., et al. Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of cystic fibrosis. Pediatr Pulmonol 32 (2001) 343-350